Key Takeaways
- Strong FY25 close, macro clouds gathering: Q4 revenue grew 4.2% QoQ, 20.7% YoY to $375.2 mn, but management flagged a slowdown in the last six weeks with customers dragging feet on deal closures amid tariff and funding uncertainty.
- AI practice is the growth engine: The Data & AI practice grew over 50% for the second consecutive year, powered by SASVA-led agentic AI wins across Fortune 1000 clients, and is reshaping commercial models toward outcome-based pricing.
- Healthcare delivered 54% full-year growth but faces a reset: Government research funding that vanished overnight is stressing the system; management is confident the pipeline outside impacted accounts can sustain growth, but the vertical’s momentum is now under a cloud.
- Margin levers are working, ambition is back-loaded: Q4 EBIT margin improved 70 bps QoQ to 15.6%; the aspirational target is 200–300 bps improvement by the $2 bn FY27 revenue mark, but growth remains priority number one over margin.
- What to watch next quarter: Whether the feet-dragging on deal closures converts to cancellations or a bookings rebound, the pace of healthcare’s pipeline conversion outside stressed accounts, and any M&A announcement given the stated appetite for a scaled European acquisition.
Demand Environment
- Q4 bookings reflect seasonality, not slowdown: The sequential decline in bookings is normal because 80% of revenue comes from the US, where the December quarter aligns with customer financial year-ends and typically sees higher renewals.
- Macro uncertainty is now real and rising: Over the last six weeks, tariff fears and funding freezes have entered customer conversations, causing a fluid environment where deals are not being cancelled but closures are being delayed. Management may need to build more pipeline and invest further in sales and marketing to compensate.
- No cancellations yet, but caution is warranted: The company has not seen any cancellations, only feet-dragging, and remains confident of delivering better than industry results within the same macro.
- Discretionary spend exposure is dismissed: Management argues Persistent is not dependent on discretionary spends, citing a vendor consolidation win as proof it can gain share in cost-takeout environments, though an analyst flagged the risk that the portfolio may be more exposed than peers.
Sandeep Kalra: "we have not seen any cancellations, let me put it straight - we have not seen any cancellations, we are seeing a certain amount of feet dragging in terms of deal closures"
Vertical Performance
| Vertical | Trend | Commentary |
|---|---|---|
| Healthcare & Life Sciences | ▲ Strong FY25, Q4 caution | Grew 33.6% YoY in Q4 and 54% for the full year, leading growth for six straight quarters. Government-funded research, clinical trial services and software equipment budgets have vanished overnight due to DOGE and USAID cuts, stressing the system. Management is reasonably confident the pipeline outside impacted accounts can sustain growth. |
| Banking & Financial Services | ▲ Accelerating | Grew 26.6% YoY in Q4 and 17.8% for the full year, with momentum picking up in the last two quarters. A large BFSI deal win last quarter drove vendor consolidation and higher sub-contracting costs. |
| Software & High-Tech | ▬ Subdued | Grew only 9.7% YoY in Q4 and 3.7% for the full year, the weakest vertical. A large multi-year SaaS provider deal for enterprise-wide SASVA adoption was a bright spot. |
| Europe | ▲ Outperforming | Led geographic growth at 30.6% YoY in Q4; a scaled European acquisition is a stated M&A priority for revenue diversification. |
| North America | ▲ Solid | Grew 21.3% YoY in Q4 and 20.6% for the full year, representing 80% of revenue and driving the seasonal Q3 bookings spike. |
AI & SASVA Platform
- Data & AI practice is the standout performer: The practice grew 56% over the last twelve months and over 50% in each of the last two years, driven by agentic AI programs with Fortune 1000 clients and SASVA-related use cases including taking over entire products from software companies on an outcome basis.
- SASVA is a deal-enablement weapon, not a disclosed P&L line: Management has no intent to announce SASVA revenues separately. The platform is used to win deals and implement at scale; even when customers do not buy SASVA outright, the pitch demonstrates capabilities that close deals. A tough macro may accelerate adoption as clients seek efficiency.
- Commercial model shift underway: The stated endeavor is to move toward outcome-driven and differentiated commercial models, retaining a relevant part of the benefit for Persistent while investing in increased R&D. Revenue and margin per employee are expected to improve over time from this AI-driven business model transformation.
- Partnership ecosystem deepening: A strategic NVIDIA partnership integrates the GenAI hub with NVIDIA Inference Microservices for agent-based AI. Google recognized Persistent as an implementation partner for its Healthcare AI Developer Foundation, and the company launched Pi-OmniKG for biomedical research with Google and Neo4J. Salesforce certifications crossed 10,000 with Agentforce adoption across 32+ customers.
- IP creation is accelerating: 15 new patents were filed in Q4, bringing the total to 35, and intangible assets on the balance sheet rose due to both acquisitions and SASVA platform investment.
Sandeep Kalra: "we are using SASVA two ways. We are using SASVA to enable deal wins at scale and implementation at scale, and a number of times when we pitch SASVA the customer may not necessarily buy SASVA but customers understand our capabilities"
Margins
| Margin walk (QoQ) | Impact |
|---|---|
| Utilization improvement | +20 bps |
| SG&A reduction | +30 bps |
| Higher earn-out credit | +20 bps |
| Favorable currency | +40 bps |
| IP revenue headwind (managed services deals with lab setup, third-party tools/licenses) | –40 bps |
| Net change → 15.6% | +70 bps |
- Full-year margin story: FY25 EBIT margin improved to 14.7% from 14.4% in FY24, a modest 30 bps expansion. The aspirational target is 200–300 bps improvement by the time the company hits the $2 bn revenue target by FY27, implying an exit margin in the 17–18% range.
- Growth first, margin second: Management was explicit that growth is priority number one and margin improvement is priority number two. SG&A investments in sales and marketing will continue in line with revenue growth, and the company will not starve growth to optimize margins.
- Utilization is at an all-time high: With few peers growing and hiring ability not a constraint, management is comfortable running a lean bench while macro uncertainty persists. Sub-contracting costs rose this quarter due to vendor consolidation on a large BFSI deal.
- OCF and DSO are healthy: Operating cash flow improved to 108.9% of PAT, and DSO improved by six days, a level management expects to sustain above 100%.
Sandeep Kalra: "growth will always be priority number one, margin improvement priority number two"
Client Metrics & Deal Wins
- Client concentration is deepening productively: The top 5 clients grew 35.3% YoY, top 10 grew 27.3%, and top 10 contribution rose to 42.2% of revenue from 40% a year ago. The number of $5M+ customers jumped from 40 to 55 over the year, indicating broad-based account expansion.
- Deal wins span the vertical mix: New engagements included a large multi-year SaaS provider deal for enterprise-wide SASVA adoption, multiple BFSI wins including the vendor consolidation deal that drove sub-contracting costs higher, and healthcare deals outside the stressed government-funded segment.
- Sub-vertical strategy is being operationalized: The company has rolled out a sub-vertical structure and hired leadership for sub-verticals across multiple areas, aiming to deepen domain specialization within existing verticals.
Capital Allocation & M&A
- Three-pronged M&A strategy reiterated: (1) A scaled acquisition in Europe or related geographies for revenue diversification; (2) capability-led acquisitions in the US for AI, micro-verticals, BFSI or healthcare; (3) horizontal Gen AI use cases, exemplified by the Starfish (contact center) and Arrka (data privacy and governance) acquisitions.
- New vertical entry will be acquisition-led: If Persistent enters manufacturing or other new verticals, it will do so through acquisitions to enter with dominant force rather than incubating organically as a weaker player. Existing verticals have enough addressable market to sustain growth for several years toward the $5 bn FY31 aspiration.
- Dividend policy balances payout and growth: The board recommended a final dividend of ₹15 per share, bringing the full-year total to ₹35 per share. The stated endeavor is to maintain a consistent payout ratio while augmenting growth through capability-led acquisitions.
- M&A pipeline is active but unannounced: Management is evaluating multiple assets at any point in time and will call a dedicated call if there is an update.
Sandeep Kalra: "if we want to go into the newer verticals whether it is manufacturing or others we may do as we go along acquisitions so that we enter it with a dominant force rather than incubate and be a weaker player in that"
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | Reach $2 bn in revenue | By end of FY27 |
| Margin aspiration | Improve EBIT margin by 200–300 bps from FY25 levels | By the time $2 bn revenue is achieved (FY27) |
| Effective tax rate | Remain in 23% to 23.5% range | Going forward |
| OCF | Sustain above 100% of PAT | Ongoing |
| Growth leadership | BFSI and Tech to lead growth, followed by Healthcare & Life Sciences | FY26 |
| M&A for new verticals | Enter manufacturing or other verticals via acquisition, not organic incubation | As opportunities arise |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue (USD) | $375.2 million, +4.2% QoQ and +20.7% YoY |
| Revenue (INR) | ₹3,242.11 crore, +5.9% QoQ and +25.2% YoY |
| Constant currency revenue growth | +4.5% QoQ, 20th sequential quarter of revenue growth |
| EBIT margin | 15.6%, +70 bps QoQ and +110 bps YoY |
| EBIT (INR) | ₹505.29 crore, +10.9% QoQ and +34.9% YoY |
| Profit after tax margin | 12.2% |
| Profit after tax (INR) | ₹395.76 crore, +25.5% YoY |
| Earnings per share | ₹25.60, +23% YoY |
| Full-year FY25 revenue (USD) | $1,409.1 million, +18.8% YoY |
| Full-year FY25 EBIT margin | 14.7%, vs 14.4% in FY24 |
| Full-year FY25 PAT margin | 11.7%, vs 11.1% in FY24 |
| Total contract value (TCV) | $517.5 million, with $329 million from new bookings |
| Annual contract value (ACV) | $350.2 million, with $198.1 million from new bookings |
| Full-year FY25 TCV | $2.1 billion, corresponding ACV of $1.5 billion |
| Top 10 customer revenue contribution | 42.2%, vs 40% in Q4 FY24 |
| Healthcare & life sciences vertical growth | +33.6% YoY |
| Banking & financial services vertical growth | +26.6% YoY |
| Software, high-tech & emerging vertical growth | +9.7% YoY |
| North America revenue growth | +21.3% YoY |
| Europe revenue growth | +30.6% YoY |
| Total headcount | 24,594, +744 YoY |
| Trailing 12-month attrition | 12.9%, vs 11.5% in Q4 FY24 |
| Billed DSO | 58 days, improved 6 days QoQ |
| OCF to PAT | 108.4% |
| Return on capital employed (ex-cash) | 39.7%, vs 35.7% in Q4 FY24 |
| Dividend per share (final recommended) | ₹15, total FY25 dividend ₹35 per share; payout ratio 39% |
| Effective tax rate | 21.7%, vs 22.6% in Q3; full-year FY25 23.2% |
| Forward contracts outstanding | $300 million at average rate ₹86.3 per dollar |
| Data & AI practice growth | 50%+ in each of the last two years |